Key Takeaways Section 1: The Patent Cliff Reframed: A Market Transformation, Not a Disaster 1.1 The Standard Narrative Gets It […]

The Drug Price Competition and Patent Term Restoration Act of 1984 — the Hatch-Waxman Act — is the single piece

Generic and biosimilar drugs saved the U.S. healthcare system $445 billion in 2023 alone, accumulating to over $2.9 trillion across

Section 1: The 505(b)(2) Value Proposition — Pricing Incremental Innovation 1.1 Why the Pathway Exists and What It Actually Does

Why Standard Patent Intelligence Is Failing You The patent cliff is no longer the right mental model. For two decades,

University Technology Transfer Offices (TTOs) sit at one of the most commercially consequential intersections in American innovation: the point where

1. Why ‘Inactive’ Is a Dangerous Word: The Strategic Case for Excipient Scrutiny The Myth That Costs Billions The word

Section 1: The Strategic Landscape: Why Patent Intelligence Has Become a Core Payer Competency The Formulary Has Become a Battlefield

1. What Paragraph IV Actually Is — and Why It Matters A Paragraph IV certification is a formal legal assertion